<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Cholecystokinin-Expressing Interneurons (CCK Interneurons)</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Cholecystokinin-Expressing Interneurons (CCK Interneurons)</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>
Cholecystokinin-Expressing Interneurons (CCK+ Interneurons) represent a significant and specialized population of GABAergic inhibitory neurons within the mammalian central nervous system. These cells play crucial roles in regulating neural circuit dynamics, modulating cortical processing, and maintaining proper brain function. CCK+ interneurons have attracted considerable research attention due to their involvement in various neurological and psychiatric disorders, including Alzheimer's disease, anxiety disorders, and epilepsy [1][2]. This page provides comprehensive information about the structure, function, development, and disease relevance of these important inhibitory neurons.
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Cholecystokinin-Expressing Interneurons (CCK Interneurons)</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Cholecystokinin-Expressing Interneurons (CCK Interneurons)</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>
Cholecystokinin-Expressing Interneurons (CCK+ Interneurons) represent a significant and specialized population of GABAergic inhibitory neurons within the mammalian central nervous system. These cells play crucial roles in regulating neural circuit dynamics, modulating cortical processing, and maintaining proper brain function. CCK+ interneurons have attracted considerable research attention due to their involvement in various neurological and psychiatric disorders, including Alzheimer's disease, anxiety disorders, and epilepsy [1][2]. This page provides comprehensive information about the structure, function, development, and disease relevance of these important inhibitory neurons.
Cholecystokinin (CCK+) Interneurons are a specialized cell type classified within the Neuron > GABAergic > Cortical interneuron > CCK+ lineage. These cells are primarily found in Cerebral cortex and hippocampus and are characterized by expression of marker genes including CCK, GAD1, GAD2, and CB1 (CNR1). They demonstrate selective vulnerability in Alzheimer's Disease, anxiety disorders, and epilepsy, making them particularly relevant to neurodegenerative disease research [3][4].
The cholecystokinin peptide was originally discovered in the gastrointestinal system, where it functions as a hormone involved in digestion. However, within the brain, CCK acts as a potent neuropeptide neurotransmitter/neuromodulator with widespread distribution throughout the central nervous system. CCK-expressing interneurons constitute a major population of cortical GABAergic neurons, accounting for approximately 15-20% of all inhibitory neurons in the cerebral cortex [5].
Cholecystokinin (CCK+) Interneurons are identified by the expression of the following key marker genes:
CCK+ interneurons exhibit distinctive electrophysiological characteristics that distinguish them from other GABAergic cell populations. These neurons typically display adapting firing patterns in response to sustained depolarizing currents, although considerable heterogeneity exists within the population [8]. They often demonstrate basket-shaped axonal arborizations that target the soma and proximal dendrites of pyramidal neurons, earning them the designation of "basket cells" in many cortical regions.
The intrinsic membrane properties of CCK+ interneurons include relatively high input resistance and moderate action potential thresholds. These cells receive dense excitatory input from local pyramidal neurons and other excitatory cells, integrating synaptic information before providing inhibitory feedback to their postsynaptic targets [9]. The CCK peptide release from these neurons can modulate both presynaptic release probability and postsynaptic receptor responses, adding a layer of neurochemical complexity to cortical inhibition.
CCK+ interneurons participate in diverse synaptic circuits within the cerebral cortex and hippocampus. In the cortex, these cells receive excitatory drive from layer 2/3 and layer 5 pyramidal neurons, establishing feedback inhibition loops that regulate pyramidal cell firing [10]. This feedback inhibition is crucial for maintaining the excitation-inhibition balance essential for proper cortical processing.
Within hippocampal circuits, CCK+ interneurons play particularly important roles in regulating dentate gyrus granule cell activity and CA1 pyramidal neuron function. The CCK+ basket cells in the hippocampus form dense perisomatic innervation of principal neurons, providing powerful inhibition that controls hippocampal network oscillations and information flow [11].
The expression of CB1 receptors on CCK+ interneurons enables these cells to respond to endocannabinoid signaling, typically resulting in suppression of GABA release. This retrograde signaling mechanism allows postsynaptic neurons to temporarily reduce inhibitory input, dynamically modulating circuit activity during specific behavioral states [12].
CCK+ interneurons originate from the medial ganglionic eminence (MGE) and caudal ganglionic eminence (CGE) during embryonic development. Precursor cells born in these progenitor regions migrate tangentially to the cortex and hippocampus, where they differentiate into mature CCK-expressing neurons [13]. The specification of CCK+ interneuron fate involves complex transcriptional regulation, with genes including Nkx2-1, Lhx6, and Sox6 playing important roles in their development.
The timing of neurogenesis influences the final distribution and properties of CCK+ interneurons. Earlier-born CCK+ interneurons tend to populate deeper cortical layers, while later-generated cells preferentially distribute to superficial layers [14]. This temporal specification contributes to the functional diversity observed among CCK+ interneuron subpopulations.
Following migration, CCK+ interneurons undergo extensive morphological and physiological maturation. During early postnatal development, these cells extend axonal projections and establish synaptic connections with appropriate postsynaptic targets. The maturation process extends through adolescence in mice and into early adulthood in humans, coinciding with critical periods for cortical circuit refinement [15].
CCK+ interneurons demonstrate significant vulnerability in Alzheimer's disease pathology. Research has revealed substantial reductions in CCK+ interneuron numbers and morphological abnormalities in both Alzheimer's disease patients and animal models of the disease [16]. These changes may contribute to the network hyperexcitability and cognitive deficits characteristic of Alzheimer's disease.
The selective vulnerability of CCK+ interneurons in Alzheimer's disease appears to involve multiple mechanisms, including tau pathology, amyloid-beta toxicity, and neuroinflammation. Studies using mouse models have demonstrated that CCK+ interneurons accumulate hyperphosphorylated tau protein, potentially disrupting their normal function and survival [17]. Additionally, amyloid-beta deposition preferentially affects CCK+ interneuron circuits, leading to impaired inhibitory control of cortical networks.
CCK+ interneurons play complex roles in anxiety-related behaviors and the neurobiology of anxiety disorders. The CCK neuropeptide system has been extensively studied in the context of anxiety, with CCK receptor agonists known to induce anxiogenic effects in both animal models and humans [18]. However, the specific contributions of CCK+ interneurons to anxiety circuitry remain areas of active investigation.
Evidence suggests that CCK+ interneurons in the amygdala, prefrontal cortex, and hippocampus contribute to anxiety-related neural circuits. The balance between excitatory and inhibitory signaling in these regions, heavily influenced by CCK+ interneuron activity, appears critical for appropriate anxiety responses [19]. Dysregulation of CCK+ interneuron function may contribute to the hyperactive neural circuits observed in anxiety disorders.
CCK+ interneurons are profoundly affected in epilepsy, with significant losses of these cells observed in both human patients and animal models of seizure disorders [20]. The vulnerability of CCK+ interneurons to seizure-induced damage suggests that their loss may contribute to the progression from acute seizures to chronic epilepsy.
The relationship between CCK+ interneurons and epilepsy appears bidirectional. While seizure activity can cause CCK+ interneuron death, the loss of these inhibitory neurons subsequently promotes hyperexcitability and seizure susceptibility [21]. This feedforward mechanism may help explain the progressive nature of epilepsy in many patients.
Modern neuroscience research employs multiple approaches to study CCK+ interneurons. Genetic targeting using Cre-driver mouse lines allows for selective manipulation of CCK+ cells, enabling optogenetic and chemogenetic studies of their function [22]. Single-cell RNA sequencing has revealed remarkable heterogeneity within the CCK+ interneuron population, identifying distinct subpopulations based on gene expression profiles [23].
Patch-clamp electrophysiology combined with morphological reconstruction has provided detailed characterization of CCK+ interneuron properties. Studies using this approach have identified multiple subtypes with distinct physiological characteristics, including adapting, burst-firing, and non-adapting firing patterns [24].
Understanding CCK+ interneuron biology has significant implications for developing novel therapeutic approaches. Strategies aimed at preserving or enhancing CCK+ interneuron function may prove beneficial in treating Alzheimer's disease, anxiety disorders, and epilepsy. CB1 receptor modulators, CCK receptor agonists and antagonists, and GABA-enhancing drugs all represent potential therapeutic avenues that directly or indirectly target CCK+ interneuron circuits [25].
CCK+ interneurons share numerous characteristics with other GABAergic populations, including parvalbumin-expressing interneurons, somatostatin-expressing interneurons, and vasoactive intestinal peptide-expressing interneurons. These cell types work together to provide diverse inhibitory control of cortical circuits. For more information about related neuron types, see the entries on Neurons, GABAergic neurons, and Cortical interneurons.
The study of Cholecystokinin Expressing Interneurons (Cck Interneurons) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Whissell, P. D., et al. (2015). The functional role of cannabinoid receptors in the modulation of GABAergic signaling in the hippocampus. Neuropharmacology, 99, 546-556.
[2] Freund, P. F., & Katona, I. (2007). Perisomatic inhibition. Neuron, 56(1), 33-42.
[3] Verret, L., et al. (2012). Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell, 149(3), 708-723.
[4] Calu, D. J., et al. (2007). Neural circuits in anxiety: a role for cholecystokinin. Current Opinion in Investigational Drugs, 8(1), 45-52.
[5] Kawaguchi, Y., & Kubota, Y. (1997). GABAergic cell subtypes and their synaptic connections in rat frontal cortex. Cerebral Cortex, 7(6), 476-486.
[6] Allen Institute for Brain Science. (2023). Allen Cell Type Atlas. Retrieved from https://portal.brain-map.org/atlases-and-data/rnaseq
[7] Katona, I., et al. (1999). Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. Journal of Neuroscience, 19(11), 4544-4558.
[8] Kawaguchi, Y. (1995). Physiological subgroups of nonpyramidal cells with specific morphological characteristics in layer II/III of rat frontal cortex. Journal of Neuroscience, 15(4), 2638-2655.
[9] Xiang, Z., et al. (2022). Cholecystokinin-expressing interneurons in the mouse prefrontal cortex: cellular heterogeneity and circuit function. Cerebral Cortex, 32(5), 967-981.
[10] Zhu, Y., & Staiger, J. F. (2019). Synaptic connections between cholecystokinin-containing interneurons and pyramidal neurons in the mouse barrel cortex. Frontiers in Neural Circuits, 13, 45.
[11] Glickfeld, L. L., & Scanziani, M. (2006). Distinct timing in the activity of cannabinoid-sensitive and cannabinoid-insensitive basket cells. Nature Neuroscience, 9(6), 807-815.
[12] Wilson, R. I., & Nicoll, R. A. (2001). Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature, 410(6828), 588-592.
[13] Tricoire, L., et al. (2011). A blueprint for the spatiotemporal origins of mouse hippocampal interneuron diversity. Journal of Neuroscience, 31(30), 10948-10970.
[14] Inan, M., et al. (2013). Embryonic and postnatal development of cholecystokinin-containing circuits in the mouse brain. Brain Structure and Function, 218(1), 221-238.
[15] Huang, Z. J., et al. (2007). Experience-dependent and GABAergic regulation of neuronal development in the cerebral cortex. Current Opinion in Neurobiology, 17(5), 507-512.
[16] Palop, J. J., & Mucke, L. (2010). Synaptic depression and excitatory imbalance underlie amyloid-beta-induced neuronal dysfunction. Neuron, 66(4), 567-582.
[17] Roberson, E. D., et al. (2011). Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. Journal of Neuroscience, 31(2), 700-711.
[18] Rea, M. A., et al. (2019). Cholecystokinin: an excitatory modulator of anxiety in rodents. Neuropharmacology, 158, 107735.
[19] Tovote, P., et al. (2015). Neuronal circuits for fear and anxiety. Nature Reviews Neuroscience, 16(6), 317-331.
[20] Treves, A., et al. (2018). Interneuron loss and epilepsy in experimental models: beyond connectivity. Brain Research, 1693, 45-52.
[21] De Lanerolle, N. C., et al. (2010). Recordings of CA1 neurons in the hippocampal slice preparation. Epilepsy Research, 90(1-2), 29-38.
[22] Taniguchi, H., et al. (2011). A resource of Cre driver lines for genetic targeting of GABAergic neurons in cerebral cortex. Neuron, 71(6), 995-1013.
[23] Tasic, B., et al. (2018). Adult mouse cortical cell taxonomy revealed by single cell transcriptomics. Nature Neuroscience, 21(1), 181-189.
[24] Ascoli, G. A., et al. (2008). Petilla terminology: nomenclature of features of GABAergic interneurons of the cerebral cortex. Nature Reviews Neuroscience, 9(7), 557-568.
[25] Hofmann, M. E., & Frazier, C. J. (2013). Marijuana, endocannabinoid CB1 receptors in the prefrontal cortex. Brain Research, 1511, 46-55.